Newsroom | 63113 results

Sorted by: Latest

General Health
-

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

IRVINE, Calif.--(BUSINESS WIRE)--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol "HIND." “Vy...
-

Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2025, Cash Dividend, and Raised FY 2025 Guidance

ADDISON, Texas--(BUSINESS WIRE)--Concentra Group Holdings Parent, Inc. (“Concentra,” the “Company,” “we,” “us,” or “our”) (NYSE: CON), the nation’s largest provider of occupational health services, today announced results for its second quarter ended June 30, 2025, the declaration of a cash dividend, and raised guidance for FY 2025. “Concentra delivered strong results in the second quarter, building on our solid start to 2025,” said Keith Newton, Chief Executive Officer of Concentra. “Our resul...
-

Adtalem Global Education Announces Exceptional Fiscal Year 2025 Results; Initiates Fiscal Year 2026 Guidance

CHICAGO--(BUSINESS WIRE)--Adtalem Global Education Announces Exceptional Fiscal Year 2025 Results; Initiates Fiscal Year 2026 Guidance...
-

FIGS Releases Second Quarter 2025 Financial Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS) (the “Company”), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its second quarter 2025 financial results and published a financial highlights presentation on its investor relations website at ir.wearfigs.com/financials/quarterly-results/. Second Quarter 2025 Financial Highlights Net revenues were $152.6 million, an increase of 5.8% year over year, primarily d...
-

Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960...
-

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “The recent expansion of our T...
-

Owlet to Simplify Capital Structure Through Exchange of Series A and Series B Warrants for Common Stock

LEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced an agreement with a majority of the holders of the Company’s Series A and Series B warrants to exchange their warrants for common stock. “We’re very pleased to simplify our capital structure through today’s announced warrant exchange,” said Jonathan Harris, Owlet’s President. “The successful exchange of these warrants will be an important milestone that we be...
-

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2025. “The data presented for all 117 patients enrolled in the registrational iMMagine-1 study continue to demonstrate anito-cel’s potential to be a life-changing therapy for mu...
-

C2N Announces Major Global Expansion, Adds Six New International Partners

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is reaching additional global healthcare providers eager to use its PrecivityAD2™ blood test to help diagnose Alzheimer’s disease. The PrecivityAD2™ blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer’s disease, for patients being evaluated for cognitive complaints through a simpl...
-

AIS Healthcare Awarded a Group Purchasing Agreement for 503A Intrathecal Compounded Medications with Premier, Inc.

DALLAS--(BUSINESS WIRE)--AIS Healthcare has been awarded a group purchasing agreement for 503A intrathecal compounded medications with Premier, Inc., effective July 1, 2025. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for sterile, patient-specific intrathecal pain pump medications. In addition, to assist with compliance policies, this agreement with Premier will provide member hospitals with site audit e...